Wed, 30th Dec 2020 08:15
LONDON, Dec 30 (Reuters) - The AstraZeneca-Oxford COVID-19
vaccine approved by Britain on Wednesday should be effective
against a rapidly spreading new variant of the virus,
AstraZeneca's Chief Executive Pascal Soriot said.
"Our belief at this point is that this vaccine should be
effective against the variant," he told BBC radio.
(Reporting by Paul Sandle, editing by William James)
(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of Engla...
FTSE 100 up 0.5%, FTSE 250 adds 0.4% *
(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the...
(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemi...
(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:
Astrazeneca (AZN)